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Canavan disease is a genetic disorder associated with optic neuropathy and the metabolism of N-acetylaspartate is defective in this
disorder due to mutations in the gene coding for the enzyme aspartoacylase II. Here we show that the plasma membrane transporter NaDC3, a
Na+-coupled transporter for dicarboxylates, is able to transport N-acetylaspartate, suggesting that the transporter may function in concert with
aspartoacylase II in the metabolism of N-acetylaspartate. Since Canavan disease is associated with ocular complications, we investigated the
expression pattern of NaDC3 and aspartoacylase II in ocular tissues in mouse by in situ hybridization. These studies show that NaDC3
mRNA is expressed in the optic nerve, most layers of the retina, retinal pigment epithelium, ciliary body, iris, and lens. Aspartoacylase II
mRNA is coexpressed in most of these cell types. We conclude that transport of N-acetylaspartate into ocular tissues via NaDC3 and its
subsequent hydrolysis by aspartoacylase II play an essential role in the maintenance of visual function.
D 2004 Elsevier B.V. All rights reserved.Keywords: N-Acetylaspartate; Sodium/dicarboxylate transporter; NaDC3; Aspartoacyalse II; Retina; RPE; Canavan disease; Optic neuropathy
1. Introduction glia, the enzyme L-aspartate-N-acetyl transferase responsibleN-Acetylaspartate (NAA) levels in the brain have been
shown to provide a sensitive measure of neuronal survival
[1,2]. As the second most abundant free amino acid in the
brain, NAA plays an essential role in many cellular processes
[1–3]. NAA functions in the protection of cells against
osmotic stress, is implicated in cell-specific signaling during
development and synthesis of the neuromodulator N-acety-
laspartylglutamate (NAAG), and is considered as an intra-
cellular source of acetyl groups essential for the synthesis of
lipids [4–7]. This compound is found predominantly in
neurons of the mature brain and is continually released from
the neurons during excitation. The concentration of NAA in
neurons has been found to be as high as 20 mM, but this
compound is barely detectable in glia [4,5,8,9]. Consistent
with the findings that NAA is present at very low levels in0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.05.009
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E-mail address: vganapat@mail.mcg.edu (V. Ganapathy).for the synthesis of NAA is found only in neurons whereas the
enzyme responsible for the breakdown of NAA, namely
aspartoacylase II, is found predominantly in glia [10,11].
Since aspartoacylase II is a cytosolic enzyme, NAA must
enter into glial cells for hydrolysis by the enzyme. Hydrolysis
of NAA by aspartoacylase II releases the acetyl group that is
used in the synthesis of lipids associated with myelination.
The functional significance of this process is evident from the
clinical consequences of Canavan disease, a debilitating and
fatal genetic disorder caused by aspartoacylase II deficiency
[12,13].
The uptake of NAA from the extracellular space by glia
has been described by Sager et al. [14]. Studies from our
laboratory have recently shown that the Na+-coupled high-
affinity dicarboxylate transporter NaDC3 is responsible for
this uptake process [15]. These studies have also demon-
strated the expression of NaDC3 in the nervous system by
Northern blot analysis, in situ hybridization, and RT-PCR
[15–17]. NaDC3 is expressed in the meningeal layers of
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cortex where expression was detectable within the astrocytes
scattered among the neuronal cells [16]. The expression
pattern of NaDC3 in the brain is similar to that of aspartoa-
cylase II [1–3]. This agrees with the suggested role of
NaDC3 in delivering extracellular NAA to intracellular sites
in glia for subsequent hydrolysis by aspartoacylase II [15].
Since transport by NaDC3 is as obligatory as the function of
aspartoacylase II in the hydrolysis of NAA within the glial
cells, we hypothesize that genetic defects in NaDC3 will
have the similar clinical consequences as aspartoacylase II
deficiency.
Patients suffering from Canavan disease often present
with optic neuropathy [12,13]. NAA is found at high levels
in neural retina [1–3]. Apparently, disruption of NAA
metabolism due to aspartoacylase II deficiency interferes
with retinal function. However, the expression pattern of this
enzyme in ocular tissues has not been investigated. Since
NaDC3 is essential for the entry of NAA into cells prior to
hydrolysis by aspartoacylase II, we hypothesized that the
transporter might also be expressed in ocular tissues where
aspartoacylase II is expressed. In the present paper, we tested
this hypothesis by examining the ability of murine NaDC3 to
transport NAA and investigating the expression pattern of
NaDC3 and aspartoacylase II in murine ocular tissues.2. Materials and methods
2.1. Materials
[2,3-3H]-Succinic acid (specific radioactivity, 37.5 Ci/
mmol) was purchased from Moravek Biochemicals (Brea,
CA, USA). Cell culture supplies, Trizol reagent, and Lip-
ofectin were purchased from Life Technologies (Gaithers-
burg, MD, USA). Restriction enzymes were from New
England Biolabs (Beverly, MA, USA). N-Acetylaspartate
was obtained from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Cloning of mouse NaDC3
A mouse kidney cDNA library [18] was screened using a
rat NaDC3 cDNA fragment as the probe. The fragment was
generated from the parent rat NaDC3 cDNA [16] by diges-
tion with EcoRI and BamHI and labeled with [a-32P]-dCTP.
Positive clones were identified on the primary screening and
the colonies were purified by secondary/tertiary screening.
Both sense and antisense strands of the cDNA were se-
quenced using an automated Perkin-Elmer Applied Biosys-
tems (Farmingham, MA) 377 Prism DNA sequencer.
2.3. Heterologous functional expression of mouse NaDC3
in mammalian cells
The function of the cloned mouse NaDC3 was character-
ized in HRPE cells (a human retinal pigment epithelial cellline) following heterologous expression of the cDNA using
the vaccinia virus expression technique [16,17]. The trans-
port function of the heterologously expressed mouse NaDC3
was measured as the uptake of [3H]-succinate in the presence
of Na+. Uptake measurements were made at room temper-
ature with an incubation period of 2 min. The composition of
the buffer used in uptake measurements was 25 mM HEPES/
Tris (pH 7.5), containing 140 mM NaCl, 5.4 mM KCl, 1.8
mM CaCl2, 0.8 mM MgSO4, and 5 mM glucose. Under no
experimental conditions employed in these studies, the
uptake of [3H]succinate exceeded 5% of [3H]succinate added
to the extracellular medium at the start of the uptake
measurement. Therefore, the concentration of radiolabel in
the medium was never a limiting factor for uptake in any of
the experiments described in this study. The experiments
were repeated two or three times with independent trans-
fections, each done in duplicate or triplicate. Data are
presented as meansF S.E. of these replicate measurements.
2.4. RT-PCR and restriction analysis
Total RNA samples isolated from mouse eyes and kidney
(positive control) were used for RT-PCR. The mouse
NaDC3-specific primers used in the analysis were 5 V-
AGGGCTGTGAGGAGTCTGGGCTATC-3 V(sense) and
5 V-GCCTGCTGCGAACAACTGTAACATC-3 V (anti-
sense). These primers correspond to the nucleotide positions
1343–1367 and 2267–2291 in the full-length mouse
NaDC3 cDNA isolated from the mouse kidney cDNA
library. The expected size of the RT-PCR product was 949
bp. The resulting product was gene-cleaned and used for
restriction analysis. Two enzymes were used in restriction
analysis: HindIII and PstI. The expected sizes of the
restriction fragments from the RT-PCR product by digestion
with these two enzymes are 734 and 215 bp for HindIII and
660 and 289 bp for PstI.
2.5. In situ hybridization
Enucleated eyes from albino mice were frozen in Tissue-
Tek OCT (Miles Laboratories, Elkhart, IN, USA), sectioned
at 10-Am thickness, and fixed in 4% paraformaldehyde.
Treatment of the sections for in situ hybridization was done
according to the method as described previously [19,20].
Hybridization signals were detected by using digoxigenin-
labeled probes and the anti-DIG-AP (the alkaline phospha-
tase-coupled anti-digoxigenin antibody) (DIG nucleic acid
detection kit, Boehringer-Mannheim, Indianapolis, IN,
USA). The color reaction was developed in NBT/BCIP
(provided in the detection kit).
For the preparation of probes specific for NaDC3, a
KpnI/HindIII digestion fragment (f 0.85 kbp) of the mouse
NaDC3 cDNA was subcloned into pSPORT vector. For the
preparation of the sense riboprobe, used as a negative
control, the subcloned plasmid was linearized with KpnI
and the cDNA insert was transcribed using SP6 RNA
Fig. 1. Substrate specificity of mouse NaDC3. Uptake of [3H]-succinate (20
nM) was measured in cells transfected with vector alone and in cells
transfected with mouse NaDC3 cDNA in the absence or in the presence of
various unlabeled dicarboxylates and monocarboxylates (2 mM). The
cDNA-specific uptake was calculated by adjusting for the endogenous
uptake activity. The cDNA-specific uptake measured in the absence of
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the subcloned plasmid was linearized with HindIII and the
cDNA insert was transcribed using T7 RNA polymerase.
The riboprobes were labeled with digoxigenin using the
digoxigenin-lebeling kit (Boehringer-Mannheim). For the
preparation of probes specific for aspartoacylase II, a RT-
PCR product specific for mouse aspartoacylase II was
generated using a primer pair designed on the basis of the
reported sequence of the mouse aspartoacylase II [21] and
poly(A)+mRNA isolated from mouse eyes. The primers
were 5 V-CATGGAAATGAACTGACCGGAGTGT-3 V
(sense) and 5 V-AACAGGATACTTGGCAATGGAACGA-
3 V(antisense). The expected size of the RT-PCR product
was 465 bp. The product was subcloned into pGEM-T
vector and sequenced to establish its identity and orienta-
tion. For the preparation of the sense riboprobe, used as a
negative control, the subcloned plasmid was linearized with
ApaI and the cDNA insert was transcribed using SP6 RNA
polymerase. For the preparation of the antisense riboprobe,
the subcloned plasmid was linearized with SalI and the
cDNA insert was transcribed using T7 RNA polymerase.
The riboprobes were labeled with digoxigenin using the
digoxigenin-labeling kit (Boehringer-Mannheim).inhibitors was taken as control (100%) and the uptake in the presence of
inhibitors is given as percent of this control value.3. Results
3.1. Succinate transport via the cloned mouse NaDC3
The cloned mouse NaDC3 cDNA is 3227-bp long with a
1803-bp-long open reading frame (including the termination
codon). The cDNA codes for a protein of 600 amino acids
and the sequence is identical to that of the recently reported
NaDC3 cloned from mouse brain [22]. The mouse NaDC3
cDNAwas functionally expressed in a heterologous expres-
sion system using HRPE cells. The uptake of succinate, a
substrate for NaDC3, was compared in control cells trans-
fected with vector alone and in cells transfected with mouse
NaDC3 cDNA. When measured in the presence of NaCl at
pH 7.5, the uptake of succinate (20 nM) in vector-trans-
fected cells was 0.06F 0.01 pmol/106 cells/2 min. The
uptake increased 85-fold to 5.08F 0.62 pmol/106 cells/2
min in cDNA-transfected cells. The cDNA-specific uptake
was obligatorily dependent on Na+ because the uptake
decreased to 3% of control when measured in the absence
of Na+.
3.2. Substrate specificity of mouse NaDC3
The substrate specificity of mouse NaDC3 was investi-
gated in this heterologous expression system by assessing
the ability of various dicarboxylates and monocarboxylates
to compete with succinate for uptake via mouse NaDC3
(Fig. 1). Unlabeled succinate (a dicarboxylate containing
four carbon atoms), malate (also a dicarboxylate containing
four carbon atoms), and a-ketoglutarate (a dicarboxylatecontaining five carbon atoms), at a concentration of 2 mM,
inhibited completely the uptake of [3H]-succinate (20 nM)
via mouse NaDC3. In contrast, the oxalate (a dicarboxylate
with two carbon atoms) and malonate (a dicarboxylate with
three carbon atoms) showed little or no inhibitory activity.
Similarly, the monocarboxylate lactate did not compete with
succinate for uptake via mouse NaDC3. These data show
that NaDC3 prefers dicarboxylates with a backbone con-
taining four or five carbon atoms as substrates. The carbon-
chain length of the backbone seems to be very critical for
recognition as a substrate because dicarboxylates with back-
bones containing less number of carbon atoms do not
interact with the transporter. Aspartate, an amino acid with
two carboxylate groups and an amino group and a backbone
with four carbon atoms, caused 75% inhibition of NaDC3-
mediated succinate uptake. The inhibitory potency of aspar-
tate increased significantly with covalent modification of the
amino group by acetylation. The resulting compound, N-
acetylaspartate (NAA), is a dicarboxylate with no positive
charge associated with the amino group. Consequently, this
derivative of aspartate is recognized as a substrate by
NaDC3 much better than aspartate. We compared the
potency of aspartate and NAA to inhibit NaDC3-mediated
succinate uptake (Fig. 2). Aspartate inhibited the uptake
with an IC50 value (i.e., concentration of the inhibitor
necessary to cause 50% inhibition) of 870F 70 AM. In
contrast, NAA inhibited the uptake with an IC50 value of
66F 10 AM. These data demonstrate that NAA interacts
with mouse NaDC3 with high affinity. We have shown
recently that rat NaDC3 is able to transport NAA with high
Fig. 2. Inhibition of NaDC3-mediated succinate uptake by aspartate and N-
acetylaspartate. Uptake of [3H]-succinate (20 nM) was measured in cells
transfected with vector alone and in cells transfected with mouse NaDC3
cDNA in the absence or in the presence of increasing concentrations of
aspartate (.) and N-acetylaspartate (o). Results represent cDNA-specific
uptake activity after adjusting for endogenous activity. Data are given as
percent of control uptake (100%) measured in the absence of inhibitors.
Fig. 4. Expression pattern of NaDC3 mRNA in mouse ocular tissues as
assessed by in situ hybridization. (A) Hematoxylin and eosin-stained
cryosection of the anterior portion of the eye showing the cornea (C), ciliary
body (CB), iris (I), and lens (L). (B) Anterior portion of the eye probed with
antisense digoxigenin-labeled mouse NaDC3 riboprobe. (C) Hematoxylin
and eosin-stained retinal section for comparison to adjacent unstained retinal
sections. Several layers of the retina are identified: GCL, ganglion cell layer;
INL, inner nuclear layer; ONL, outer nuclear layer; IS, inner segment; RPE,
retinal pigment epithelium. (D) Retina probed with antisense digoxigenin-
labeled mouse NaDC3 riboprobe. (E) Optic nerve probed with antisense
digoxigenin-labeled mouse NaDC3 riboprobe. (F) Optic nerve probed with
sense digoxigenin-labeled mouse NaDC3 riboprobe (negative control).
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coupled manner [15]. The results with mouse NaDC3
obtained in the present study are comparable to those
obtained with rat NaDC3.
We also performed similar dose-response studies for
succinate, a-ketoglutarate, and malate to determine the
IC50 values for these compounds from their abilities
to inhibit the uptake of [3H] succinate (20 nM) (data
not shown). The values were 17F 4, 17F 3, and 27F 3
AM for succinate, a-ketoglutarate, and malate, respectively.Fig. 3. Evidence for the expression of NaDC3 mRNA in mouse eye. Total RNA, isolated from mouse eyes, was used for RT-PCR with primers specific for
mouse NaDC3. The RT-PCR product was gene-cleaned and used for digestion with HindIII and PstI. Uncut and digested samples were size-fractionated in
parallel along with DNA markers to estimate the sizes of the RT-PCR product and the restriction fragments. Total RNA, isolated from mouse kidneys, was used
as a positive control.
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NAA is about two- to fourfold less than that for the
dicarboxylates.
3.3. Evidence for the expression of NaDC3 in ocular tissues
The expression of NaDC3 in ocular tissues was deter-
mined in the mouse eye by RT-PCR and in situ hybridiza-
tion. RT-PCR using mouse eye total RNA and mouse
NaDC3-specific primers yielded a product of expected size
(949 bp) based on the nucleotide positions of the primers in
mouse NaDC3 cDNA (Fig. 3). Since the cDNA was cloned
from mouse kidney, RT-PCR was done with the same pair of
primers using mouse kidney total RNA as a positive control.
The molecular identity of the RT-PCR products was estab-
lished by restriction analysis. With two different enzymes
(HindIII and PstI), the restriction pattern of the RT-PCR
products from the eye and kidney was similar and the sizes
of the restriction fragments were as expected from the
restriction map of the mouse NaDC3 cDNA.
3.4. Expression pattern of NaDC3 mRNA in mouse eye
In situ hybridization experiments were carried out using
frozen sections of adult mouse eyes. The expression of
NaDC3 mRNA as assessed by the labeling with a mouse
NaDC3-specific antisense riboprobe was evident in the
retina and in other parts of the eye (Fig. 4). A low
magnification of a hematoxylin and eosin-stained section
of the anterior part of the eye is shown in Fig. 4A. The
results of in situ hybridization in this section are shown inFig. 5. Expression pattern of aspartoacylase II mRNA in mouse ocular tissues
digoxigenin-labeled mouse aspartoacylase II riboprobe. Different layers of the reti
outer nuclear layer; IS, inner segment; RPE, retinal pigment epithelium. (B) Highe
digoxigenin-labeled mouse aspartoacylase II riboprobe (C, cornea; CB, ciliary bod
aspartoacylase II riboprobe (negative control).Fig. 4B. The ciliary body and iris are intensely positive for
NaDC3 mRNA as are the epithelial cells at the equator and
periphery of the lens. A hematoxylin and eosin-stained
section of the retina is shown in Fig. 4C. The results of in
situ hybridization in this section, shown in Fig. 4D, dem-
onstrate abundant expression of NaDC3 mRNA in the
neurons of the ganglion cell layer, cells of the inner nuclear
layer and the inner segments of the photoreceptor cells. The
retinal pigment epithelial cells that constitute part of the
blood-retinal barrier also express NaDC3 mRNA. The optic
nerve also shows intense positive reaction, primarily in the
glial columns, for the presence of NaDC3 mRNA as shown
in Fig. 4E. The sense riboprobe did not yield a positive
signal in the optic nerve (Fig. 4F) or anywhere else in the
eye (not shown) under identical experimental conditions,
demonstrating the specificity of the signals seen with the
antisense riboprobe.
3.5. Expression pattern of aspartoacylase II mRNA in
mouse eye
NaDC3 is the transporter that is responsible for the
uptake of extracellular NAA into cells. Since aspartoacylase
II, the enzyme responsible for the hydrolysis of NAA, is a
cytosolic enzyme, NaDC3 and aspartoacyalse II must func-
tion in a coordinated manner in the breakdown of extracel-
lular NAA. This would predict a similar expression pattern
for these two proteins in cell types involved in NAA
metabolism. Fig. 5 describes the expression pattern of
aspartoacylase II mRNA in ocular tissues. The expression
was evident, as indicated by the hybridization signals with aas assessed by in situ hybridization. (A) Retina probed with antisense
na are identified: GCL, ganglion cell layer; INL, inner nuclear layer; ONL,
r magnification of (A). (C) Anterior portion of the eye probed with antisense
y; I, iris; L, lens). (D) Retina probed with sense digoxigenin-labeled mouse
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ganglion cell layer, cells of the inner nuclear layer and inner
segments of the photoreceptor cells as well as in retinal
pigment epithelial cells (Fig. 5A and B). The iris and, to a
lesser extent, the ciliary body were also positive for expres-
sion of this enzyme (Fig. 5C). The epithelial cells at the
periphery of the lens were also positive for the hybridization
signals. There was no positive signal with the sense ribop-
robe under identical experimental conditions (Fig. 5D).4. Discussion
We have demonstrated here that the murine NaDC3 is
able to transport N-acetylaspartate (NAA) with high affinity.
Acetylation of the amino group in aspartate increases the
affinity for NaDC3 several-fold. These findings may have
physiological significance. NAA is the second most abun-
dant amino acid in the nervous system, only glutamate
occurring at higher concentrations [1–3]. Glial cells express
a Na+-coupled transport system for NAA [14]. Interestingly,
the characteristics of NAA transport in glial cells are similar
to those of NAA transport via NaDC3. It is very likely that
NaDC3 is responsible for the observed transport of NAA in
glial cells. Neurons synthesize NAA and intraneuronal
concentrations of this compound are usually in the range
of 10–15 mM [1–3]. NAA is released from the neurons by
a hitherto unknown mechanism and the extracellular con-
centration of NAA in the brain interstitial space is f 100
AM [1–3]. Glial cells possess aspartoacylase II, the enzyme
responsible for breakdown of NAA [10,11]. Therefore,
NAA has to first enter the glial cells from the extracellular
space for subsequent hydrolysis by aspartoacylase II. Thus,
NaDC3 and aspartoacylase II must function in a coordinated
manner in the breakdown of NAA. The brain content of
NAA is decreased in pathological conditions associated
with neuronal loss because NAA, released from the de-
ceased neurons, is efficiently broken down by glial cells.
This is the basis of the current clinical use of measurements
of NAA in the brain by proton magnetic resonance spec-
troscopy to assess neuronal loss in various pathological
conditions associated with disorders of the central nervous
system [1–3].
NAA functions as an important source of acetyl groups
in the synthesis of brain lipids, a process closely related
to the process of myelination [7]. Several cerebral pathol-
ogies such as multiple sclerosis, hypothyroidism, and
mitochondrial encephalopathies with a dysfunction of the
myelination process are associated with alterations in the
content and metabolism of NAA in the brain [23,24]. The
importance of NAA metabolism in myelination is under-
scored by the clinical consequences of a genetic defect in
aspartoacylase II. Canavan disease is an autosomal reces-
sive disorder with mutations in the gene coding for
aspartoacylase II [12,13]. This is a neurodegenerative
disease of infancy and early childhood characterized bydemyelination, leukodystrophy, megaloencephalopathy,
and spongiform degeneration. Recent studies have shown
that targeted disruption of the gene coding for this
enzyme in mice produces central nervous system pathol-
ogies similar to those observed in patients with Canavan
disease [25]. Since NaDC3 functions in a concerted
manner with aspartoacylase II in the hydrolysis of
NAA, we hypothesize that dysfunction of the transporter
may also lead to similar clinical consequences.
Since Canavan disease is also associated with dysfunc-
tion of the retinal and optic nerve [12,13], the metabolism of
NAA apparently plays an important role in the eye. The
presence of NAA has been demonstrated in the retina [1–3].
But, there is no information available in the literature on the
expression of aspartoacylase II nor NaDC3. We speculated
that aspartoacylase II and NaDC3, which are both obliga-
tory for the metabolism of NAA, are expressed in the neural
retina. In the present study, we provide evidence that
supports this speculation. NaDC3 mRNA, as assessed by
in situ hybridization, is expressed in several layers of the
neural retina. The expression is evident in the ganglion
cells, photoreceptor cells and in the optic nerve. A similar
pattern of expression is also seen with aspartoacylase II.
These findings suggest that the metabolism of NAA is
disrupted in Canavan disease not only in the brain but also
in the neural retina, thus providing the molecular basis for
the retinal and optic nerve dysfunction in the disease.
NaDC3 and aspartoacylase II are expressed in glial cells
as expected from the published reports on the predominant
metabolism of NAA associated with these cells. Interest-
ingly, these two proteins are also expressed in neuronal cells
such as the retinal ganglion cells and the photoreceptor
cells. The nonneuronal cells such as the retinal pigment
epithelial cells and the cells of the ciliary body, iris, and lens
are also positive for the expression of NaDC3 and aspar-
toacylase II. The physiological relevance of the expression
of NaDC3 and aspartoacylase II in these sites remains to be
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